Blueprint Medicines (BPMC) PT Lowered to $151 at Wells Fargo
Tweet
Share
E-mailGet Alerts BPMC Hot Sheet
Price: $129.46 --0%
Rating Summary:
11 Buy, 18 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 10 | Down: 7 | New: 64
Rating Summary:
11 Buy, 18 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 10 | Down: 7 | New: 64
Join SI Premium – FREE
Wells Fargo analyst Derek Archila lowered the price target on Blueprint Medicines (NASDAQ: BPMC) to $151.00 (from $153.00) while maintaining a Overweight rating.
You May Also Be Interested In
- Designer Brands (DBI) PT Lowered to $6 at UBS
- TETRA Technologies Inc. (TTI) PT Lowered to $10 at Northland
- Ascendis Pharma (ASND) PT Raised to $312 at Oppenheimer
Create E-mail Alert Related Categories
Analyst PT ChangeSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
